Tryptase beta-2
Homo sapiens
State in the Current Structure
| Assembly | Oligomeric State | Construct | Mutations and Modifications | Ligands, Ions and Associated Components | Method and Experimental Conditions | Structure Quality |
|---|---|---|---|---|---|---|
| 1 | Protein homooligomer Homooligomer Protein × 4 PDB declaration: tetrameric(4) Consistent with protein copy count | Chain A; UniProt 31–275 Chain B; UniProt 31–275 Chain C; UniProt 31–275 Chain D; UniProt 31–275 | Not recorded | C3A ALLYL {(1S)-1-[(5-{4-[(2,3-DIHYDRO-1H-INDEN-2-YLAMINO)CARBONYL]BENZYL}-1,2,4-OXADIAZOL-3-YL)CARBONYL]-3-PYRROLIDIN-3-YLPROPYL}CARBAMATE × 4 | X-RAY DIFFRACTION X-ray crystallization conditions:VAPOR DIFFUSION, HANGING DROP;293 K;2mg/mL protein, 10 mM MES, pH 6.1, 2M NaCl dissolved in 0.1 M NaOAc, pH 4.6, 0.2 M ammonium sulfate, 30% PEG 1500. Crystallization drops were set up using various ratios of protein solution to crystallization solution. Crystals appropriate for diffraction studies appeared in 2-5 days at room temperature, VAPOR DIFFUSION, HANGING DROP, temperature 293.0K | Resolution 2.50 Å R-free 0.259 |
Other States of the Same Protein in the Database
Each row is a biological assembly of the same UniProt protein in another PDB entry. The “Difference from current entry” column identifies evidence-level differences; no tag means the currently parsed fields agree.
| Other PDB | Difference from Current Entry 2FXR | Assembly / Oligomeric State | Construct | Mutations and Modifications | Ligands, Ions and Non-polymers | Method and Experimental Conditions | Structure Quality |
|---|---|---|---|---|---|---|---|
| 1A0L HUMAN BETA-TRYPTASE: A RING-LIKE TETRAMER WITH ACTIVE SITES FACING A CENTRAL PORE Deposited 1997-12-03 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer;Protein × 4 PDB declaration: tetrameric |
Chain A
31–274(244 aa)
Chain B
31–274(244 aa)
Chain C
31–274(244 aa)
Chain D
31–274(244 aa)
|
Not recorded | APA (2S)-3-(4-carbamimidoylphenyl)-2-hydroxypropanoic acid × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 5;pH 5.0
|
Resolution 3.00 Å R-free 0.276 |
| 2BM2 human beta-II tryptase in complex with 4-(3-Aminomethyl-phenyl)- piperidin-1-yl-(5-phenethyl- pyridin-3-yl)-methanone Deposited 2005-03-09 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer;Protein × 4 PDB declaration: tetrameric |
Chain A
31–275(245 aa)
Chain B
31–275(245 aa)
Chain C
31–275(245 aa)
Chain D
31–275(245 aa)
|
Not recorded | PM2 1-[3-(1-{[5-(2-PHENYLETHYL)PYRIDIN-3-YL]CARBONYL}PIPERIDIN-4-YL)PHENYL]METHANAMINE × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
291 K;PEG 3000 13-19%. NA.ACETATE 100 MM PH 5. T=18 DEG C. TAKES ABOUT 3 DAYS TO GET 200 MICROMETRE SILEX SHAPED CRYSTALS
|
Resolution 2.20 Å R-free 0.259 |
| 2FPZ Human tryptase with 2-amino benzimidazole Deposited 2006-01-17 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer;Protein × 4 PDB declaration: tetrameric |
Chain A
31–275(245 aa)
Chain B
31–275(245 aa)
Chain C
31–275(245 aa)
Chain D
31–275(245 aa)
|
Not recorded | AX7 1H-benzimidazol-2-amine × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION;pH 4.6;281 K;0.1M sodium acetate, 0.2M ammonium sulfate, 30% PEG 1500, pH 4.6, VAPOR DIFFUSION, temperature 281K
|
Resolution 2.00 Å R-free 0.240 |
| 2FS8 Human beta-tryptase II with inhibitor CRA-29382 Deposited 2006-01-21 | Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer;Protein × 4 PDB declaration: tetrameric |
Chain A
31–275(245 aa)
Chain B
31–275(245 aa)
Chain C
31–275(245 aa)
Chain D
31–275(245 aa)
|
Not recorded | C3A ALLYL {(1S)-1-[(5-{4-[(2,3-DIHYDRO-1H-INDEN-2-YLAMINO)CARBONYL]BENZYL}-1,2,4-OXADIAZOL-3-YL)CARBONYL]-3-PYRROLIDIN-3-YLPROPYL}CARBAMATE × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 4.6;293 K;2mg/mL protein in 10mM MES, pH 6.1, 2M NaCl mixed in reservoir solution containing 0.1 M NaOAc, pH 4.6, 0.2 M ammonium sulfate, 30% PEG 1500. Crystallization drops were set up using various ratios of protein solution to crystallization solution. Crystals appropriate for diffraction studies appeared in 2-5 days at room temperature, VAPOR DIFFUSION, HANGING DROP, temperature 293.0K
|
Resolution 2.50 Å R-free 0.250 |
| 2FS9 Human beta tryptase II with inhibitor CRA-28427 Deposited 2006-01-21 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer;Protein × 4 PDB declaration: tetrameric |
Chain A
31–275(245 aa)
Chain B
31–275(245 aa)
Chain C
31–275(245 aa)
Chain D
31–275(245 aa)
|
Not recorded | C4A ETHYL {(1S)-5-AMINO-1-[(5-{4-[(2,3-DIHYDRO-1H-INDEN-2-YLAMINO)CARBONYL]BENZYL}-1,2,4-OXADIAZOL-3-YL)CARBONYL]PENTYL}CARBAMATE × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 4.6;293 K;2mg/mL protein in 10mM MES, pH 6.1, 2M NaCl mixed with reservoir solution containing 0.1 M NaOAc, pH 4.6, 0.2 M ammonium sulfate, 30% PEG 1500. Crystallization drops were set up using various ratios of protein solution to crystallization solution. Crystals appropriate for diffraction studies appeared in 2-5 days at room temperature, VAPOR DIFFUSION, HANGING DROP, temperature 293.0K
|
Resolution 2.30 Å R-free 0.254 |
| 2FWW human beta-tryptase II complexed with 4-piperidinebutyrate to make acylenzyme Deposited 2006-02-03 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer;Protein × 4 PDB declaration: tetrameric |
Chain A
31–275(245 aa)
Chain B
31–275(245 aa)
Chain C
31–275(245 aa)
Chain D
31–275(245 aa)
|
Not recorded | C1R 4-PIPERIDINEBUTYRATE × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
293 K;2mg/mL of protein, 10 mM MES, pH 6.1, 2M NaCl was mixed with crystallization solution 0.1 M NaOAc, pH 4.6, 0.2 M ammonium sulfate, 30% PEG 1500. Crystallization drops were set up using various ratios of protein solution to crystallization solution. Crystals appropriate for diffraction studies appeared in 2-5 days at room temperature, VAPOR DIFFUSION, HANGING DROP, temperature 293.0K
|
Resolution 2.25 Å R-free 0.257 |
| 2GDD Human beta II tryptase with inhibitor CRA-27592 Deposited 2006-03-15 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer;Protein × 4 PDB declaration: tetrameric |
Chain A
31–275(245 aa)
Chain B
31–275(245 aa)
Chain C
31–275(245 aa)
Chain D
31–275(245 aa)
|
Not recorded | 5AM BENZYL {(1S)-5-AMINO-1-[(S)-HYDROXY(5-{[4-(4-PHENYLBUTANOYL)PIPERAZIN-1-YL]METHYL}-1,2,4-OXADIAZOL-3-YL)METHYL]PENTYL}CARBAMATE × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION;pH 4.6;293 K;Tryptase was purchased from Promega (catalog #G563X). The protein was formulated as a 2 mg/mL solution in 10 mM MES (pH 6.1) and 2M NaCl, and was crystallized from a solution of 0.1 M NaoAc (pH 4.6), 0.2 M ammonium sulfate and 30% PEG 1500 (all reagents obtained from Hampton Research). Crystallization drops were set up at various ratios of protein solution to crystallization solution. Crystals appeared in 2-5 days at room temperature., VAPOR DIFFUSION, temperature 293.0K
|
Resolution 2.35 Å R-free 0.254 |
| 5F03 TRYPTASE B2 IN COMPLEX WITH 5-(3-Aminomethyl-phenoxymethyl)-3-[3-(2-chloro-pyridin-3-ylethynyl)-phenyl]-oxazolidin-2-one; compound with trifluoro-acetic acid Deposited 2015-11-27 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric |
Chain A
31–275(245 aa)
|
Mutation:NO | 5TA (5~{S})-5-[[3-(aminomethyl)phenoxy]methyl]-3-[3-[2-(2-chloranylpyridin-3-yl)ethynyl]phenyl]-1,3-oxazolidin-2-one × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 7.5;293 K;20% PEG 10000, 0.1 M HEPES
|
Resolution 1.94 Å R-free 0.200 |
| 5F03 TRYPTASE B2 IN COMPLEX WITH 5-(3-Aminomethyl-phenoxymethyl)-3-[3-(2-chloro-pyridin-3-ylethynyl)-phenyl]-oxazolidin-2-one; compound with trifluoro-acetic acid Deposited 2015-11-27 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric |
Chain B
31–275(245 aa)
|
Mutation:NO | 5TA (5~{S})-5-[[3-(aminomethyl)phenoxy]methyl]-3-[3-[2-(2-chloranylpyridin-3-yl)ethynyl]phenyl]-1,3-oxazolidin-2-one × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 7.5;293 K;20% PEG 10000, 0.1 M HEPES
|
Resolution 1.94 Å R-free 0.200 |
| 9QFU Human Tryptase beta-2 (hTPSB2) complexed with covalent inhibitor Compound #1 Deposited 2025-03-12 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer;Protein × 4 PDB declaration: tetrameric |
Chain A
31–273(243 aa)
Chain B
31–273(243 aa)
Chain C
31–273(243 aa)
Chain D
31–273(243 aa)
|
Not recorded | A1I52 ~{N}-[(1~{S},2~{S})-6-azanyl-1-[5-[[4-[2-(3,4-dichlorophenyl)ethoxy]phenyl]methyl]-1,2,4-oxadiazol-3-yl]-1-oxidanyl-hexan-2-yl]-4-fluoranyl-benzamide × 4 SO4 SULFATE ION × 16 PEG DI(HYDROXYETHYL)ETHER × 2 EDO 1,2-ETHANEDIOL × 15 ACT ACETATE ION × 3 GOL GLYCEROL × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION;293 K;The protein was formulated as a 2 mg/mL solution in 10 mM MES (pH 6.1) and 2M NaCl, and was crystallized from a solution of 0.1 M NaoAc (pH 4.6), 0.2 M ammonium sulfate and 30% PEG 1500
|
Resolution 1.98 Å R-free 0.221 |
| 9QFV Human Tryptase beta-2 (hTPSB2) Deposited 2025-03-12 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer;Protein × 4 PDB declaration: tetrameric |
Chain A
31–275(245 aa)
Chain B
31–275(245 aa)
Chain C
31–275(245 aa)
Chain D
31–275(245 aa)
|
Not recorded | ACT ACETATE ION × 4 EDO 1,2-ETHANEDIOL × 13 SO4 SULFATE ION × 8 GOL GLYCEROL × 4 MES 2-(N-MORPHOLINO)-ETHANESULFONIC ACID × 4 1PE PENTAETHYLENE GLYCOL × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION;pH 4.6;293 K;The protein was formulated as a 2 mg/mL solution in 10 mM MES (pH 6.1) and 2M NaCl, and was crystallized from a solution of 0.1 M NaoAc (pH 4.6), 0.2 M ammonium sulfate and 30% PEG 1500
|
Resolution 2.06 Å R-free 0.219 |
10 other PDB entries and 11 assemblies. Open the comparison page and filter oligomeric states
View Construct and Data Evidence
| UniProt name | TRYB2_HUMAN |
| Isoform | — |
| PDB entities | 1 |
| Chains and sequence ranges | Author chain A; PDBConstruct 1–245; UniProt 31–275 Author chain B; PDBConstruct 1–245; UniProt 31–275 Author chain C; PDBConstruct 1–245; UniProt 31–275 Author chain D; PDBConstruct 1–245; UniProt 31–275 |